...Sarah L. Lutterman; Nitash Zwaveling-Soonawala; Hein J. Verberne; Frederik A. Verburg; A.S. Paul van Trotsenburg; Christiaan F. Mooij Background: Graves’s disease (GD) is the most common cause of hyperthyroidism. Maximal 30% of pediatric GD patients achieve remission with antithyroid drugs...

...Gerd Krause; Anja Eckstein; Ralf Schülein Autoimmune thyroid-stimulating antibodies are activating the thyrotropin receptor (TSHR) in both the thyroid and the eye, but different molecular mechanisms are induced in both organs, leading to Graves’ disease (GD) and Graves’ orbitopathy (GO...

...Annabel S. Zaat; Joep P.M. Derikx; Nitash Zwaveling-Soonawala; A.S. Paul van Trotsenburg; Christiaan F. Mooij Background: Graves’ disease (GD) is the most common cause of hyperthyroidism. In children, the overall relapse frequency after treatment with antithyroid drugs is high. Therefore, many...

... research both from the perspective of “what is known” and of methodologies for its investigation. It then summarises the evidence for a role for the microbiome in the pathogenesis of Graves’ disease and Graves’ orbitopathy with reference to animal models and studies in human cohorts, from both published...

...Hirosuke Danno; Eijun Nishihara; Kazuyoshi Kousaka; Tomohiko Nakamura; Toshihiko Kasahara; Takumi Kudo; Mitsuru Ito; Shuji Fukata; Mitsushige Nishikawa; Akira Miyauchi Introduction: Marine-Lenhart syndrome (MLS) is now understood to be a combination of Graves’ disease and autonomously functioning...

... dysfunction in univariable analysis, but not in multivariable analysis. However, little is known on the dose-dependent influence of ATDs on the difference in FT4 levels between maternal and cord blood in patients with Graves’ disease (GD) [ 2, 9 ]. In this connection, future research proposed by the ATA...

...Tanja Diana; Hans-Peter Holthoff; Julia Fassbender; Christian Wüster; Michael Kanitz; George J. Kahaly; Martin Ungerer Introduction: A novel long-term murine model for Graves’ disease (GD) using repeated, long-term immunizations with recombinant adenovirus expressing the extracellular A-subunit...

...Terry J. Smith Background: Thyroid-associated ophthalmopathy (TAO), an autoimmune process affecting the tissues surrounding the eye, most commonly develops in individuals with Graves’ disease. It is disfiguring, can cause vision loss, and dramatically lessens the quality of life in patients...

...- or hypothyroidism. Case Presentation: A 31-year-old male patient with suppressed thyroid-stimulating hormone (TSH), elevated free thyroxine and free triiodothyronine, along with high thyroid receptor antibodies was diagnosed with Graves’ disease. Benzylthiouracil was started. One month later, reduced sensitivity...

...Diana Grove-Laugesen; Sofie Malmstroem; Eva Ebbehoj; Anne Lene Riis; Torquil Watt; Lars Rejnmark; Klavs Würgler Hansen Introduction and Objective: The excess cardiovascular morbidity and mortality in hyperthyroidism and Graves’ disease (GD) is inadequately understood. We aimed to elucidate whether...

...Tanja Diana; Paul D. Olivo; Yie-Hwa Chang; Christian Wüster; Michael Kanitz; George J. Kahaly Objective: Stimulating thyrotropin-receptor antibodies (TSAb) cause Graves’ disease (GD). We tested a novel homogeneous fluorescent 3′,5′ cyclic adenine monophosphate (cAMP) assay for the detection of TSAb...

...Jun Yang; Meng-Jie Dong; Qin Xu Graves’ disease Pretibial myxedema Radioiodine Pretibial myxedema (PTM) is an uncommon autoimmune manifestation of Graves’s disease. It is commonly associated with ophthalmopathy and typically localized in the pretibial region [ 1 ]. It is speculated...

...Shi Hui Junice Wong Background: Radioiodine (RAI) therapy for Graves’ disease is a well-accepted and effective treatment with a good side effect profile. Short-term adverse effects can occasionally include radiation-induced thyroiditis. To my knowledge, cervical lymphadenitis associated with RAI...

... hyperthyroidism (Graves’ disease) is rare. We describe a case of a Graves’ disease induced by anti-PD-1 therapy and we review the previous reports on this issue. Case Presentation: A 51-year-old man developed an overt autoimmune hyperthyroidism 2 months after he had started nivolumab (anti-PD-1) therapy...

... transplantation (BMT/HSCT). In both alemtuzumab-induced TD and HIV/HAART patients, the commonest disorder is Graves’ disease (GD), followed by hypothyroidism and thyroiditis; Graves’ orbitopathy is observed in some GD patients. On the contrary, GD is rare post-BMT/HSCT, where hypothyroidism predominates probably...

...Cosimo Rodia; Francesca Menconi; Laura Mazoni; Liborio Torregrossa; Fulvio Basolo; Paolo Vitti; Claudio Marcocci; Michele Marinò Background: The pathogenesis of the extrathyroidal manifestations of Graves’ disease (GD) is not fully clarified. According to the most common hypothesis, they would...

...’ disease following restoration of a euthyroid state. Methodology: This was an observational study with a before-after study design. Forty-five treatment-naïve adults with Graves’ diseases were included and 36 completed the study. An oral glucose tolerance test was performed at baseline and after 3 months...

...Ola Lindgren; Pernilla Asp; Anna Sundlöv; Jan Tennvall; Bushra Shahida; Tereza Planck; Peter Åsman; Mikael Lantz Background: In Graves’ disease (GD), immunocompetent cells infiltrate thyroid tissue with release of TSH-receptor antibodies (TRAb), and radioiodine treatment is known to elicit...

...Roberto Negro; Laszlo Hegedüs; Roberto Attanasio; Enrico Papini; Kristian H. Winther Objective: Selenium (Se) supplementation has been suggested in the treatment of Graves’ disease (GD). We sought to investigate Se prescription patterns for GD across European countries. Methods: Members...

... polymorphisms (SNPs) in DIO2 were associated with several diseases. The association of SNPs in DIO2 with Graves’ disease (GD) was suggested in 2 Russian studies. Objectives: The aim of the study was to examine whether SNPs in DIO2 are associated with GD or Graves’ ophthalmopathy (GO). Methods: Seven SNPs...